Skip to Content

Amgen Inc AMGN Stock Quote

| Rating as of


Market Open

| Currency in USD

  • Last Close 267.70
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Value
  • Day Range 265.01  –  267.81
  • Year Range 211.71  –  296.67
  • Market Cap 142.7063 Bil
  • Volume / Avg 956,454.0 /  2.5 Mil
  • Price / Sales 5.41
  • Price / Book 21.12
  • Forward Div Yield 3.85%
  • Trailing Div Yield 3.12%

Morningstar‘s Stock Analysis AMGN

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Biopharma Industry: Medicare Drug Price Negotiation Impact Reduced by Expected Generic Pressures

Damien Conover Sector Director

Analyst Note

| Damien Conover |

As part of the Inflation Reduction Act, the U.S. Department of Health and Human Services on Aug. 29 announced the first 10 drugs selected for mandated 2026 Medicare price negotiations. This doesn’t have a major impact on our valuations or moat ratings for the biopharma industry. The 10 drugs have been on the market for a prolonged period (seven years for small-molecule drugs and 11 years for biologics) and were selected based on the largest gross (before discounts) spending in Medicare Part D.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics AMGN

Company Profile AMGN

Business Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).

One Amgen Center Drive
Thousand Oaks, CA, 91320-1799
Industry Drug Manufacturers - General
Employees 25,200

Related Articles AMGN

Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of AMGN’s competitive advantage.

Amgen Inc


Regeneron Pharmaceuticals Inc


Novartis AG Registered Shares

−$0.88 (0.33%) +$7.33 (0.89%) +$0.56 (0.61%)
Market Cap
142.71 Bil90.34 Bil191.31 Bil
Drug Manufacturers - General Biotechnology Drug Manufacturers - General

* Trading data in this section is delayed by at least 15 minutes.

FAQs for Amgen Inc Stock

Yes. AMGN has a forward dividend yield of 3.18%. See AMGN’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

AMGN’s market cap is 142.71 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

AMGN’s stock style is Large Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

AMGN’s price/sales is 5.41.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

AMGN’s price/forward earnings is 18.04.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

AMGN’s price/book is 21.12.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See AMGN’s valuation ratios compared to the Market Index.

AMGN’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare AMGN’s historical performance against its industry peers and the overall market.